RecruitingNot Applicable

The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study

Australia500 participantsStarted 2023-03-14

Plain-language summary

To determine the long term outcomes of Endoscopic Submucosal Dissection (ESD), Endoscopic Full Thickness Resection (EFTR) and Submucosal-Tunnelling Endoscopic Resection (STER) for upper gastrointestinal neoplastic lesions

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * UGI neoplastic lesions \> 10mm * Lesions for ESD limited to the mucosal and/or submucosal layer OR * Lesions for EFTR limited to the muscularis propria layer OR * Lesions for STER limited to the submucosal and/or muscularis propria layer * Aged 18 years or older Exclusion Criteria: * Age less than 18 * Unable to give informed consent * Pregnant or lactating patients * Patients with bleeding diathesis or who cannot discontinue ADP blockers (e.g. clopidogrel, prasugrel) or antithrombotics (e.g. warfarin, dabigatran) periprocedurally

What they're measuring

Effectiveness of endoscopic resection of UGI neoplastic lesions: completeness of resection

Timeframe: 2 weeks

Safety: intra and post procedural; bleeding; perforation; anaesthetic

Timeframe: 30 day

Long term outcomes: recurrent and residual disease

Timeframe: 3 years

Trial details

NCT IDNCT05804331

SponsorWestern Sydney Local Health District

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-03-14

Contact for this trial

Michael Bourke

02 8890 5555 michael@citywestgastro.com.au

View on ClinicalTrials.gov More Cancer of Stomach trials